• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sarah Cannon Research Institute (SCRI) - Articles and news items

Lilly and SCRI team up to develop investigational oncology therapy

Industry news / 17 June 2015 /

Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor…

 

Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +